RA Capital Management’s Verve Therapeutics VERV Stock Holding History

RA Capital Management’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-310,284	Closed	-$7.08M	–	100
2022 Q1	$7.08M	Hold	310,284	–	–	0.15%	84
2021 Q4	$11.4M	Sell	310,284 -570,000	-65%	-$23.9M	0.2%	79
2021 Q3	$41.4M	Hold	880,284	–	–	0.57%	44
2021 Q2	$53M	Buy	+880,284	New	+$36.5M	0.85%	38

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RA Capital Management's VERV Position: Q2 2022 in Review

RA Capital Management sold out of Verve Therapeutics (VERV) in Q2 2022, closing a stake of 310,284 shares — an estimated $7.08M sold.

RA Capital Management first reported a position in VERV in Q2 2021 and held it in 4 quarters. The position peaked at $53M in Q2 2021. 101 funds tracked by Wall St. Rank hold VERV as of Q2 2022.

RA Capital Management reported no remaining Verve Therapeutics position as of Q2 2022 after selling out during the quarter.
RA Capital Management sold 310,284 Verve Therapeutics shares in Q2 2022, an estimated $7.08M.
RA Capital Management first reported a position in Verve Therapeutics in Q2 2021 and held it in 4 quarters.
RA Capital Management's Verve Therapeutics position peaked at $53M in Q2 2021.
101 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2022.

Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.